OncoMatch/Clinical Trials/NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Is NCT05579366 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Rina-S and Carboplatin for high grade epithelial ovarian cancer.
Treatment: Rina-S · Carboplatin · Bevacizumab · Pembrolizumab — This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Ovarian Cancer
Endometrial Cancer
Non-Small Cell Lung Carcinoma
Mesothelioma
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Allowed: BRCA1 deleterious mutation
Allowed: BRCA2 deleterious mutation
Prior therapy
Must have received: platinum-based chemotherapy
Must have received: anti-vegf therapy (bevacizumab)
Must have received: parp inhibitor — maintenance
Must have received: anti-pd-l1 therapy
Cannot have received: topoisomerase 1 inhibitor-based antibody-drug conjugate
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USOR HonorHealth · Phoenix, Arizona
- USOR Arizona Oncology Associates · Tucson, Arizona
- University of California Los Angeles Medical Center · Los Angeles, California
- University of California, San Diego; Moores Cancer Center · San Diego, California
- USOR Sansum Clinic · Santa Barbara, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05579366 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior topoisomerase 1 inhibitor-based antibody-drug conjugate disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages